| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | gsk |
| Uniprot No | P0AEW6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-434aa |
| 氨基酸序列 | MKFPGKRKSKHYFPVNARDPLLQQFQPENETSAAWVVGIDQTLVDIEAKVDDEFIERYGLSAGHSLVIEDDVAEALYQELKQKNLITHQFAGGTIGNTMHNYSVLADDRSVLLGVMCSNIEIGSYAYRYLCNTSSRTDLNYLQGVDGPIGRCFTLIGESGERTFAISPGHMNQLRAESIPEDVIAGASALVLTSYLVRCKPGEPMPEATMKAIEYAKKYNVPVVLTLGTKFVIAENPQWWQQFLKDHVSILAMNEDEAEALTGESDPLLASDKALDWVDLVLCTAGPIGLYMAGFTEDEAKRKTQHPLLPGAIAEFNQYEFSRAMRHKDCQNPLRVYSHIAPYMGGPEKIMNTNGAGDGALAALLHDITANSYHRSNVPNSSKHKFTWLTYSSLAQVCKYANRVSYQVLNQHSPRLTRGLPEREDSLEESYWDR |
| 预测分子量 | 55.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GSK重组蛋白相关研究的3篇参考文献示例：
1. **文献名称**：Efficacy of the Herpes Zoster Subunit Vaccine in Adults Aged 50 Years or Older
**作者**：Cunningham AL, et al.
**摘要**：该研究报道了GSK重组带状疱疹疫苗Shingrix的Ⅲ期临床试验结果，证明其对50岁以上成年人的疱疹后神经痛预防有效率达90%以上，并展示了良好的安全性。
2. **文献名称**：Long-term immunogenicity of a recombinant hepatitis B vaccine (Engerix-B) in healthy adults
**作者**：Coates T, et al.
**摘要**：研究评估了GSK重组乙肝疫苗Engerix-B的长期免疫原性，发现接种后10年仍能维持高水平抗体，支持其作为长效预防手段的有效性。
3. **文献名称**：Development and evaluation of AS01. an adjuvant system containing α-tocopherol and saponin QS-21
**作者**：Garçon N, et al.
**摘要**：本文详细描述了GSK专利佐剂系统AS01的研发，该佐剂通过增强Th1免疫反应显著提升了重组蛋白疫苗(如Shingrix)的效力，并探讨了其作用机制。
4. **文献名称**：Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
**作者**：Schmidt ME, et al.
**摘要**：研究报道了GSK基于重组RSV融合前F蛋白的疫苗在老年人群中的Ⅱ期试验结果，显示其可诱导高水平中和抗体且耐受性良好，为后续开发奠定基础。
注：上述文献标题及内容基于公开研究整合，具体细节建议通过学术数据库进一步验证。
**Background of GSK's Recombinant Protein Therapeutics**
GlaxoSmithKline (GSK), a global pharmaceutical leader, has pioneered the development of recombinant protein therapeutics by leveraging advancements in genetic engineering and biotechnology. Recombinant proteins are engineered by inserting DNA sequences encoding therapeutic proteins into host cells (e.g., bacteria, yeast, or mammalian cells), which then produce the target protein at scale. This technology emerged in the 1980s, aligning with GSK’s strategic focus on innovative biologics to address unmet medical needs.
GSK’s recombinant protein portfolio spans vaccines, monoclonal antibodies, and immunotherapies. A landmark achievement includes its recombinant protein-based vaccines, such as *Shingrix* (for shingles), which combines a viral glycoprotein antigen with a novel adjuvant to enhance immune response. This reflects GSK’s expertise in adjuvant systems, a key differentiator in vaccine efficacy.
The company also focuses on infectious diseases and oncology. For instance, its recombinant RSV vaccine for older adults targets the fusion (F) glycoprotein of respiratory syncytial virus, demonstrating high efficacy in clinical trials. Additionally, GSK collaborates with academic and biotech partners to optimize protein expression systems, ensuring high yield, purity, and stability.
GSK integrates cutting-edge platforms like structural biology and AI-driven protein design to enhance therapeutic precision. Sustainability and ethical practices underpin its manufacturing processes, aligning with global regulatory standards.
By advancing recombinant protein science, GSK continues to address complex diseases, reinforcing its role in transforming biopharmaceutical innovation into real-world health solutions.
×
